Ursodeoxycholic acid

When ATH:
A05AA02

Characteristic.

Primary bile acid, normally produced in the body in small amounts and makes up about 5% common pool of bile acids, significant concentrations determined in the bile of bears some species. White or slightly yellowish powder, consisting of crystalline particles, bitter taste. Freely soluble in ethanol, glacial acetic acid, slightly soluble in chloroform, it is soluble in ether, practically insoluble in water.

Pharmacological action.
Cholelitolitic, zhelchegonnoe, gepatoprotektivnoe, hypocholesteremic, immunomodulatory.

Application.

Cholesterol gallstones, hepatitis (chronic, incl. atypical forms of chronic autoimmune, acute viral), NASH, toxic (incl. Alcoholic, Medicinal) liver disease, primary biliary cirrhosis and liver cystic fibrosis, primary sclerosing cholangitis, atresia of the intrahepatic biliary tract, cholestasis during parenteral nutrition, biliary dyskinesia, biliary reflux gastritis and reflux esophagitis; Chronic opistorhoz; prevention of liver damage when using hormonal contraceptives and cytostatics.

Contraindications.

Hypersensitivity, acute inflammatory diseases of the gallbladder, bile ducts and intestines, complete obstruction of the biliary tract, calcified gallstones, cirrhosis decompensated, expressed by the human kidney, pancreas.

Restrictions apply.

Childhood (relevant research cholelitolitic UDHL effect on the age of children to be held). Studies in children with cholestatic liver disease and biliary atresia have not identified specific pediatric problems, that would restrict the use of medicines in children.

Pregnancy and breast-feeding.

When pregnancy is possible, if the effect of therapy outweighs the potential risk to the fetus (adequate and well-controlled studies of the safety of use in pregnant women were not conducted). Caution is required when appointing lactating women (unknown, PM gets there in breast milk).

Side effects.

Diarrhea or constipation, nausea, epigastric pain and right upper quadrant, calcination gallstones, increase in liver transaminases, allergic reactions (rash and itching). In the treatment of primary biliary cirrhosis may be a transitory decompensated cirrhosis, which disappears after canceling PM.

Cooperation.

The aluminum-containing antacids, cholestyramine and colestipol bind ursodeoxycholic acid in the gut, reduce its absorption and weaken the effectiveness. Lipid-lowering drugs (particularly clofibrate), Estrogens, neomycin, progestins may increase the saturation of bile with cholesterol and reduce the ability of UDCA to dissolve cholesterol gallstones.

Dosing and Administration.

Inside (not chewing and drinking plenty of fluids). The dosage regimen and duration of treatment set individually; the average dose of 8-10 mg / kg / day.

Precautions.

Prolonged (more 1 Months) the treatment requires monthly monitoring of liver transaminases, Alkaline phosphatase, GGT and bilirubin in the blood (particularly in the first 3 months of therapy). The effectiveness of the treatment must be confirmed by X-rays and ultrasound of biliary tract (every six months). In order to prevent a recurrence of cholelithiasis should continue treatment for several months after the dissolution of stones.

During treatment, women of childbearing age should use reliable methods of contraception.

Cautions.

Positive results can be achieved only if there is a pure cholesterol (roentgen) gallstones no larger than 15-20 mm, with preserved function of the gallbladder and permeability of the cystic and common bile ducts.

Cooperation